Cargando…

Administration of JTE013 abrogates experimental asthma by regulating proinflammatory cytokine production from bronchial epithelial cells

BACKGROUND: Sphingosine-1-phosphate (S1P) is a bioactive phospholipid that acts as a signal transducer by binding to S1P receptors (S1PR) 1 to 5. The S1P/S1PRs pathway has been associated with remodeling and allergic inflammation in asthma, but the expression pattern of S1PR and its effects on non-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Terashita, Tomomi, Kobayashi, Kazuyuki, Nagano, Tatsuya, Kawa, Yoshitaka, Tamura, Daisuke, Nakata, Kyosuke, Yamamoto, Masatsugu, Tachihara, Motoko, Kamiryo, Hiroshi, Nishimura, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103479/
https://www.ncbi.nlm.nih.gov/pubmed/27829417
http://dx.doi.org/10.1186/s12931-016-0465-x
_version_ 1782466600749760512
author Terashita, Tomomi
Kobayashi, Kazuyuki
Nagano, Tatsuya
Kawa, Yoshitaka
Tamura, Daisuke
Nakata, Kyosuke
Yamamoto, Masatsugu
Tachihara, Motoko
Kamiryo, Hiroshi
Nishimura, Yoshihiro
author_facet Terashita, Tomomi
Kobayashi, Kazuyuki
Nagano, Tatsuya
Kawa, Yoshitaka
Tamura, Daisuke
Nakata, Kyosuke
Yamamoto, Masatsugu
Tachihara, Motoko
Kamiryo, Hiroshi
Nishimura, Yoshihiro
author_sort Terashita, Tomomi
collection PubMed
description BACKGROUND: Sphingosine-1-phosphate (S1P) is a bioactive phospholipid that acts as a signal transducer by binding to S1P receptors (S1PR) 1 to 5. The S1P/S1PRs pathway has been associated with remodeling and allergic inflammation in asthma, but the expression pattern of S1PR and its effects on non-immune cells have not been completely clarified. The aim of this study was to examine the contribution of the signaling of S1P and S1PRs expressed in airway epithelial cells (ECs) to asthma responses in mice. METHODS: Bronchial asthma was experimentally induced in BALB/c mice by ovalbumin (OVA) sensitization followed by an OVA inhalation challenge. The effects of S1PR antagonists on the development of asthma were analyzed 24 h after the OVA challenge. RESULTS: Immunohistological analysis revealed S1PR1-3 expression on mouse airway ECs. Quantitative real-time polymerase chain reaction demonstrated that S1P greatly stimulated the induction of CCL3 and TIMP2 mRNA in human airway ECs, i.e., BEAS-2B cells, in a dose-dependent manner. Pretreatment with the S1PR2 antagonist JTE013 inhibited the CCL3 gene expression in BEAS-2B cells. Immunohistological analysis also showed that the expression level of CCL3 was attenuated by JTE013 in asthmatic mice. Furthermore, JTE013 as well as anti-CCL3 antibody attenuated allergic responses. Intratracheal administration of JTE013 also attenuated eosinophilic reactions in bronchoalveolar lavage fluids. S1P induced transcription factor NFκB activation, while JTE013 greatly reduced the NFκB activation. CONCLUSIONS: JTE013 attenuated allergic airway reactions by regulating CCL3 production from bronchial ECs. The intratracheal administration of JTE013 may be a promising therapeutic strategy for bronchial asthma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12931-016-0465-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5103479
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51034792016-11-10 Administration of JTE013 abrogates experimental asthma by regulating proinflammatory cytokine production from bronchial epithelial cells Terashita, Tomomi Kobayashi, Kazuyuki Nagano, Tatsuya Kawa, Yoshitaka Tamura, Daisuke Nakata, Kyosuke Yamamoto, Masatsugu Tachihara, Motoko Kamiryo, Hiroshi Nishimura, Yoshihiro Respir Res Research BACKGROUND: Sphingosine-1-phosphate (S1P) is a bioactive phospholipid that acts as a signal transducer by binding to S1P receptors (S1PR) 1 to 5. The S1P/S1PRs pathway has been associated with remodeling and allergic inflammation in asthma, but the expression pattern of S1PR and its effects on non-immune cells have not been completely clarified. The aim of this study was to examine the contribution of the signaling of S1P and S1PRs expressed in airway epithelial cells (ECs) to asthma responses in mice. METHODS: Bronchial asthma was experimentally induced in BALB/c mice by ovalbumin (OVA) sensitization followed by an OVA inhalation challenge. The effects of S1PR antagonists on the development of asthma were analyzed 24 h after the OVA challenge. RESULTS: Immunohistological analysis revealed S1PR1-3 expression on mouse airway ECs. Quantitative real-time polymerase chain reaction demonstrated that S1P greatly stimulated the induction of CCL3 and TIMP2 mRNA in human airway ECs, i.e., BEAS-2B cells, in a dose-dependent manner. Pretreatment with the S1PR2 antagonist JTE013 inhibited the CCL3 gene expression in BEAS-2B cells. Immunohistological analysis also showed that the expression level of CCL3 was attenuated by JTE013 in asthmatic mice. Furthermore, JTE013 as well as anti-CCL3 antibody attenuated allergic responses. Intratracheal administration of JTE013 also attenuated eosinophilic reactions in bronchoalveolar lavage fluids. S1P induced transcription factor NFκB activation, while JTE013 greatly reduced the NFκB activation. CONCLUSIONS: JTE013 attenuated allergic airway reactions by regulating CCL3 production from bronchial ECs. The intratracheal administration of JTE013 may be a promising therapeutic strategy for bronchial asthma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12931-016-0465-x) contains supplementary material, which is available to authorized users. BioMed Central 2016-11-09 2016 /pmc/articles/PMC5103479/ /pubmed/27829417 http://dx.doi.org/10.1186/s12931-016-0465-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Terashita, Tomomi
Kobayashi, Kazuyuki
Nagano, Tatsuya
Kawa, Yoshitaka
Tamura, Daisuke
Nakata, Kyosuke
Yamamoto, Masatsugu
Tachihara, Motoko
Kamiryo, Hiroshi
Nishimura, Yoshihiro
Administration of JTE013 abrogates experimental asthma by regulating proinflammatory cytokine production from bronchial epithelial cells
title Administration of JTE013 abrogates experimental asthma by regulating proinflammatory cytokine production from bronchial epithelial cells
title_full Administration of JTE013 abrogates experimental asthma by regulating proinflammatory cytokine production from bronchial epithelial cells
title_fullStr Administration of JTE013 abrogates experimental asthma by regulating proinflammatory cytokine production from bronchial epithelial cells
title_full_unstemmed Administration of JTE013 abrogates experimental asthma by regulating proinflammatory cytokine production from bronchial epithelial cells
title_short Administration of JTE013 abrogates experimental asthma by regulating proinflammatory cytokine production from bronchial epithelial cells
title_sort administration of jte013 abrogates experimental asthma by regulating proinflammatory cytokine production from bronchial epithelial cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103479/
https://www.ncbi.nlm.nih.gov/pubmed/27829417
http://dx.doi.org/10.1186/s12931-016-0465-x
work_keys_str_mv AT terashitatomomi administrationofjte013abrogatesexperimentalasthmabyregulatingproinflammatorycytokineproductionfrombronchialepithelialcells
AT kobayashikazuyuki administrationofjte013abrogatesexperimentalasthmabyregulatingproinflammatorycytokineproductionfrombronchialepithelialcells
AT naganotatsuya administrationofjte013abrogatesexperimentalasthmabyregulatingproinflammatorycytokineproductionfrombronchialepithelialcells
AT kawayoshitaka administrationofjte013abrogatesexperimentalasthmabyregulatingproinflammatorycytokineproductionfrombronchialepithelialcells
AT tamuradaisuke administrationofjte013abrogatesexperimentalasthmabyregulatingproinflammatorycytokineproductionfrombronchialepithelialcells
AT nakatakyosuke administrationofjte013abrogatesexperimentalasthmabyregulatingproinflammatorycytokineproductionfrombronchialepithelialcells
AT yamamotomasatsugu administrationofjte013abrogatesexperimentalasthmabyregulatingproinflammatorycytokineproductionfrombronchialepithelialcells
AT tachiharamotoko administrationofjte013abrogatesexperimentalasthmabyregulatingproinflammatorycytokineproductionfrombronchialepithelialcells
AT kamiryohiroshi administrationofjte013abrogatesexperimentalasthmabyregulatingproinflammatorycytokineproductionfrombronchialepithelialcells
AT nishimurayoshihiro administrationofjte013abrogatesexperimentalasthmabyregulatingproinflammatorycytokineproductionfrombronchialepithelialcells